June 9th 2022
Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.
May 4th 2022
Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.
April 28th 2022
Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.
March 1st 2022
Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
January 21st 2022
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.
November 19th 2021
Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.
September 11th 2021
Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.
June 10th 2021
Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.
December 1st 2020
Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.
October 23rd 2020
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
October 15th 2020
Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.
September 11th 2020
Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.
September 9th 2020
Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.
August 17th 2020
Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.
August 13th 2020
Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.
August 10th 2020
Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.
August 3rd 2020
Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
July 23rd 2020
Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.
July 17th 2020
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.
April 16th 2020
Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.